

Addition of icosapent ethyl cuts CV risk in patients with prior PCI

March 24 2022



The risk for cardiovascular events is reduced in statin-treated patients

with elevated triglycerides and a history of percutaneous coronary intervention (PCI) who receive icosapent ethyl, according to a study published online March 2 in the *Journal of the American Heart Association*.

Benjamin E. Peterson, M.D., M.P.H., from Harvard Medical School in Boston, and colleagues conducted a post-hoc analysis focused on a subset of patients enrolled in the multicenter Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial (REDUCE-IT). All patients included in the post hoc analysis had a prior PCI, had been treated with a stable dose of statins for at least four weeks, and had low-density lipoprotein cholesterol

Citation: Addition of icosapent ethyl cuts CV risk in patients with prior PCI (2022, March 24) retrieved 7 July 2023 from <https://medicalxpress.com/news/2022-03-addition-icosapent-ethyl-cv-patients.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.